Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195027 | PMC |
| http://dx.doi.org/10.1016/j.mehy.2020.109766 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Critical analysis of Echinacea preparations marketed in Germany.
Naunyn Schmiedebergs Arch Pharmacol
November 2024
Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Article Synopsis
- - Colds lead to significant work incapacity in 2023, impacting the German economy, with Echinacea products being popular as immune boosters and gaining attention during the COVID-19 pandemic.
- - A study examined 22 Echinacea herbal preparations, highlighting inconsistencies in their ingredients and formulations, despite their similar market presentation.
- - To better match clinical research with real-world products, new studies should analyze the actual compositions of these preparations and consider factors like dosage and work incapacity as outcomes.
Identification of South African Plant-Based Bioactive Compounds as Potential Inhibitors against the SARS-CoV-2 Receptor.
Pharmaceuticals (Basel)
June 2024
Department of Pharmacy, University of Tadulako, Palu 94118, Indonesia.
The expected progress in SARS-CoV-2 vaccinations, as anticipated in 2020 and 2021, has fallen short, exacerbating global disparities due to a lack of universally recognized "safe and effective" vaccines. This study focuses on extracts of South African medicinal plants, and , to identify metabolomic bioactive compounds inhibiting the binding of the SARS-CoV-2 spike protein to ACE2 receptors. The extracts were monitored for cytotoxicity using a resazurin cell viability assay and xCELLigence real-time cell analyzer.
View Article and Find Full Text PDFKey Clinical Message: and manages mild COVID-19 in 7 days.
Abstract: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can lead to severe complications and deaths. The search for phytotherapeutic agents to augment the fight against the current COVID-19 pandemic is therefore of highest priority.
Investigation of the interactions of HSA and SARS-CoV-2 papain-like protease against eugenol for novel COVID-19 drug discovery: spectroscopic and insilico study.
J Biomol Struct Dyn
November 2023
Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
Coronavirus family consist of a member known as SARS-CoV-2, spread drastically in 2019 (Covid-19), affecting millions of people worldwide. Till date there is no clear-clinical therapy or drug, targeted to cure this serious disease. Researches are going on to prevent this corona virus.
View Article and Find Full Text PDFA comprehensive review on modulation of SIRT1 signaling pathways in the immune system of COVID-19 patients by phytotherapeutic melatonin and epigallocatechin-3-gallate.
J Food Biochem
December 2022
Department of Biochemistry, Deshbandhu College, Delhi University, New Delhi, India.
SARS-CoV-2 infection has now become the world's most significant health hazard, with the World Health Organization declaring a pandemic on March 11, 2020. COVID-19 enters the lungs through angiotensin-converting enzyme 2 (ACE2) receptors, alters various signaling pathways, and causes immune cells to overproduce cytokines, resulting in mucosal inflammation, lung damage, and multiple organ failure in COVID-19 patients. Although several antiviral medications have been effective in managing the virus, they have not been effective in lowering the inflammation and symptoms of the illness.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!